AL 8810

a prostaglandin F(2alpha) receptor antagonist; structure in first source

Also Known As:

9,15-dihydroxy-11-fluoro-15-(2-indanyl)-16,17,18,19,20-pentanor-5,13-prostadienoic acid; AL-8810; 5-Heptenoic acid, 7-((1R,2R,3S,5S)-2-((1E,3R)-3-(2,3-dihydro-1H-inden-2-yl)-3-hydroxy-1-propen-1-yl)-3-fluoro-5-hydroxycyclopentyl)-, (5Z)-

Networked: 7 relevant articles (3 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Sharif, Najam A: 2 articles (12/2020 - 01/2019)
2.	Klimko, Peter G: 1 article (01/2019)
3.	Bek, Toke: 1 article (08/2015)
4.	Kringelholt, Sidse: 1 article (08/2015)
5.	Oversø Hansen, Pernille: 1 article (08/2015)
6.	Simonsen, Ulf: 1 article (08/2015)
7.	Awaji, T: 1 article (11/2014)
8.	Iwasa, K: 1 article (11/2014)
9.	Maruyama, K: 1 article (11/2014)
10.	Suzuki, S: 1 article (11/2014)

Related Diseases

1.	Stroke (Strokes) 01/01/2019 - "Additionally, AL-8810 has demonstrated therapeutic efficacy as an FP receptor antagonist in animal models of stroke, traumatic brain injury, multiple sclerosis, allodynia and endometriosis. "
2.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 10/01/2012 - "Mice that were treated with AL-8810 had 35.7±6.3% less neurologic dysfunction and 36.4±6.0% smaller infarct volumes than did vehicle-treated mice after 48h of permanent middle cerebral artery occlusion (pMCAO); FP(-/-) mice also had improved outcomes after pMCAO. "
3.	Neurologic Manifestations (Neurological Manifestations) 10/01/2012 - "Mice that were treated with AL-8810 had 35.7±6.3% less neurologic dysfunction and 36.4±6.0% smaller infarct volumes than did vehicle-treated mice after 48h of permanent middle cerebral artery occlusion (pMCAO); FP(-/-) mice also had improved outcomes after pMCAO. "
4.	Multiple Sclerosis 01/01/2019 - "Additionally, AL-8810 has demonstrated therapeutic efficacy as an FP receptor antagonist in animal models of stroke, traumatic brain injury, multiple sclerosis, allodynia and endometriosis. "
5.	Infarction (Infarctions) 10/01/2012 - "Mice that were treated with AL-8810 had 35.7±6.3% less neurologic dysfunction and 36.4±6.0% smaller infarct volumes than did vehicle-treated mice after 48h of permanent middle cerebral artery occlusion (pMCAO); FP(-/-) mice also had improved outcomes after pMCAO. "

Related Drugs and Biologics

1.	prostaglandin F2alpha receptor
2.	Cuprizone
3.	NG-Nitroarginine Methyl Ester (L-NAME)
4.	Nitric Oxide Synthase (NO Synthase)
5.	Retinaldehyde (Retinal)
6.	Prostaglandins F
7.	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
8.	Ibuprofen (Motrin)
9.	Angiotensin II
10.	Olopatadine Hydrochloride (Patanol)